The report highlights Daiichi Sankyo's 2025 Vision to become a ""Global Pharma Innovator with competitive advantage in oncology."" It outlines the company's strategic initiatives, including its 5-year business plan, growth beyond FY2017 LOE, establishing a foundation of sustainable growth, and its commitment to corporate social responsibility (CSR) activities. The report emphasizes the company's key initiatives in oncology, pain management, and other areas, as well as its dedication to improving access to healthcare and environmental sustainability.
Issuing Company Daiichi Sankyo Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 2.84 MB
No. of Pages 53 pages
Reporting periodApril 1, 2015-March 31, 2016
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue